1
|
Grasso D, Galderisi S, Santucci A, Bernini A. Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology. Int J Mol Sci 2023; 24:ijms24065819. [PMID: 36982893 PMCID: PMC10054308 DOI: 10.3390/ijms24065819] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2023] [Revised: 03/09/2023] [Accepted: 03/16/2023] [Indexed: 03/30/2023] Open
Abstract
Whenever a protein fails to fold into its native structure, a profound detrimental effect is likely to occur, and a disease is often developed. Protein conformational disorders arise when proteins adopt abnormal conformations due to a pathological gene variant that turns into gain/loss of function or improper localization/degradation. Pharmacological chaperones are small molecules restoring the correct folding of a protein suitable for treating conformational diseases. Small molecules like these bind poorly folded proteins similarly to physiological chaperones, bridging non-covalent interactions (hydrogen bonds, electrostatic interactions, and van der Waals contacts) loosened or lost due to mutations. Pharmacological chaperone development involves, among other things, structural biology investigation of the target protein and its misfolding and refolding. Such research can take advantage of computational methods at many stages. Here, we present an up-to-date review of the computational structural biology tools and approaches regarding protein stability evaluation, binding pocket discovery and druggability, drug repurposing, and virtual ligand screening. The tools are presented as organized in an ideal workflow oriented at pharmacological chaperones' rational design, also with the treatment of rare diseases in mind.
Collapse
Affiliation(s)
- Daniela Grasso
- Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, 53100 Siena, Italy
| | - Silvia Galderisi
- Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, 53100 Siena, Italy
| | - Annalisa Santucci
- Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, 53100 Siena, Italy
| | - Andrea Bernini
- Department of Biotechnology, Chemistry, and Pharmacy, University of Siena, 53100 Siena, Italy
| |
Collapse
|
2
|
GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders. Pharmaceuticals (Basel) 2022; 15:ph15070823. [PMID: 35890122 PMCID: PMC9325019 DOI: 10.3390/ph15070823] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 06/28/2022] [Accepted: 06/29/2022] [Indexed: 12/07/2022] Open
Abstract
Pharmaceutical chaperones (PCs) are small compounds able to bind and stabilize misfolded proteins, allowing them to recover their native folding and thus their biological activity. In particular, lysosomal storage disorders (LSDs), a class of metabolic disorders due to genetic mutations that result in misfolded lysosomal enzymes, can strongly benefit from the use of PCs able to facilitate their translocation to the lysosomes. This results in a recovery of their catalytic activity. No PC for the GCase enzyme (lysosomal acid-β-glucosidase, or glucocerebrosidase) has reached the market yet, despite the importance of this enzyme not only for Gaucher disease, the most common LSD, but also for neurological disorders, such as Parkinson’s disease. This review aims to describe the efforts made by the scientific community in the last 7 years (since 2015) in order to identify new PCs for the GCase enzyme, which have been mainly identified among glycomimetic-based compounds.
Collapse
|
3
|
Scafuri B, Verdino A, D'Arminio N, Marabotti A. Computational methods to assist in the discovery of pharmacological chaperones for rare diseases. Brief Bioinform 2022; 23:6590149. [PMID: 35595532 DOI: 10.1093/bib/bbac198] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 04/13/2022] [Accepted: 04/28/2022] [Indexed: 12/21/2022] Open
Abstract
Pharmacological chaperones are chemical compounds able to bind proteins and stabilize them against denaturation and following degradation. Some pharmacological chaperones have been approved, or are under investigation, for the treatment of rare inborn errors of metabolism, caused by genetic mutations that often can destabilize the structure of the wild-type proteins expressed by that gene. Given that, for rare diseases, there is a general lack of pharmacological treatments, many expectations are poured out on this type of compounds. However, their discovery is not straightforward. In this review, we would like to focus on the computational methods that can assist and accelerate the search for these compounds, showing also examples in which these methods were successfully applied for the discovery of promising molecules belonging to this new category of pharmacologically active compounds.
Collapse
Affiliation(s)
- Bernardina Scafuri
- Department of Chemistry and Biology "A. Zambelli", University of Salerno, via Giovanni Paolo II, 132, 84084 Fisciano (SA), Italy
| | - Anna Verdino
- Department of Chemistry and Biology "A. Zambelli", University of Salerno, via Giovanni Paolo II, 132, 84084 Fisciano (SA), Italy
| | - Nancy D'Arminio
- Department of Chemistry and Biology "A. Zambelli", University of Salerno, via Giovanni Paolo II, 132, 84084 Fisciano (SA), Italy
| | - Anna Marabotti
- Department of Chemistry and Biology "A. Zambelli", University of Salerno, via Giovanni Paolo II, 132, 84084 Fisciano (SA), Italy
| |
Collapse
|
4
|
Beckmann M, Lloyd AJ, Wilson T, Torres DPM, Goios ACL, Willis ND, Lyons L, Phillips H, Mathers JC, Nash RJ, Sharp H, Draper J. Calystegines are Potential Urine Biomarkers for Dietary Exposure to Potato Products. Mol Nutr Food Res 2020; 64:e2000515. [PMID: 32918337 DOI: 10.1002/mnfr.202000515] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 06/25/2020] [Indexed: 12/27/2022]
Abstract
SCOPE Metabolites derived from specific foods present in urine samples can provide objective biomarkers of food intake (BFIs). This study investigated the possibility that calystegines (a class of iminosugars) may provide BIFs for potato (Solanum tuberosum L.) product exposure. METHODS AND RESULTS Calystegine content is examined in published data covering a wide range of potato cultivars. Rapid methods are developed for the quantification of calystegines in cooked potato products and human urine using triple quadrupole mass spectrometry. The potential of calystegines as BFIs for potato consumption is assessed in a controlled food intervention study in the United Kingdom and validated in an epidemiological study in Portugal. Calystegine concentrations are reproducibly above the quantification limit in first morning void urines the day after potato consumption, showing a good dose-response relationship, particularly for calystegine A3 . The design of the controlled intervention mimicks exposure to a typical UK diet and showed that neither differences in preparation/cooking method or influence of other foods in the diet has significant impact on biomarker performance. Calystegine biomarkers also perform well in the independent validation study. CONCLUSION It is concluded that calystegines have many of the characteristics needed to be considered as specific BFIs for potato product intake.
Collapse
Affiliation(s)
- Manfred Beckmann
- Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3DA, UK
| | - Amanda J Lloyd
- Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3DA, UK
| | - Thomas Wilson
- Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3DA, UK
| | - Duarte P M Torres
- Faculty of Nutrition and Food Sciences, University of Porto, Rua Dr. Roberto Frias, Porto, 4200-465, Portugal.,Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
| | - Ana C L Goios
- Faculty of Nutrition and Food Sciences, University of Porto, Rua Dr. Roberto Frias, Porto, 4200-465, Portugal.,Epidemiology Research Unit, Institute of Public Health, University of Porto, Porto, Portugal
| | - Naomi D Willis
- Human Nutrition Research Centre, Population Health Sciences Institute, William Leech Building, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK
| | - Laura Lyons
- Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3DA, UK
| | - Helen Phillips
- Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3DA, UK
| | - John C Mathers
- Human Nutrition Research Centre, Population Health Sciences Institute, William Leech Building, Newcastle University, Newcastle-upon-Tyne, NE2 4HH, UK
| | - Robert J Nash
- PhytoQuest Ltd, Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, UK
| | - Hazel Sharp
- PhytoQuest Ltd, Plas Gogerddan, Aberystwyth, Ceredigion, SY23 3EB, UK
| | - John Draper
- Institute of Biological, Environmental and Rural Sciences, Aberystwyth University, Aberystwyth, SY23 3DA, UK
| |
Collapse
|
5
|
Clemente F, Matassini C, Faggi C, Giachetti S, Cresti C, Morrone A, Paoli P, Goti A, Martínez-Bailén M, Cardona F. Glucocerebrosidase (GCase) activity modulation by 2-alkyl trihydroxypiperidines: Inhibition and pharmacological chaperoning. Bioorg Chem 2020; 98:103740. [PMID: 32200326 DOI: 10.1016/j.bioorg.2020.103740] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 02/26/2020] [Accepted: 03/07/2020] [Indexed: 12/22/2022]
Abstract
The enzyme glucocerebrosidase (GCase) has become an important therapeutic target due to its involvement in pathological disorders consequent to enzyme deficiency, such as the lysosomal storage Gaucher disease (GD) and the neurological Parkinson disease (PD). Pharmacological chaperones (PCs) are small compounds able to stabilize enzymes when used at sub-inhibitory concentrations, thus rescuing enzyme activity. We report the stereodivergent synthesis of trihydroxypiperidines alkylated at C-2 with both configurations, by means of the stereoselective addition of Grignard reagents to a carbohydrate-derived nitrone in the presence or absence of Lewis acids. All the target compounds behave as good GCase inhibitors, with IC50 in the micromolar range. Moreover, compound 11a behaves as a PC in fibroblasts derived from Gaucher patients bearing the N370/RecNcil mutation and the homozygous L444P mutation, rescuing the activity of the deficient enzyme by up to 1.9- and 1.8-fold, respectively. Rescues of 1.2-1.4-fold were also observed in wild-type fibroblasts, which is important for targeting sporadic forms of PD.
Collapse
Affiliation(s)
- F Clemente
- Department of Chemistry 'Ugo Schiff', University of Firenze, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy
| | - C Matassini
- Department of Chemistry 'Ugo Schiff', University of Firenze, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy.
| | - C Faggi
- Department of Chemistry 'Ugo Schiff', University of Firenze, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy
| | - S Giachetti
- Department of Chemistry 'Ugo Schiff', University of Firenze, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy
| | - C Cresti
- Department of Chemistry 'Ugo Schiff', University of Firenze, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy
| | - A Morrone
- Paediatric Neurology Unit and Laboratories, Neuroscience Department, Meyer Children's Hospital, and Department of Neurosciences, Pharmacology and Child Health, University of Florence, Viale Pieraccini n. 24, 50139 Firenze, Italy
| | - P Paoli
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Morgagni 50, 50134 Florence, Italy
| | - A Goti
- Department of Chemistry 'Ugo Schiff', University of Firenze, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy; Associated with Consorzio Interuniversitario Nazionale di ricerca in Metodologie e Processi Innovativi di Sintesi (CINMPIS), Italy
| | - M Martínez-Bailén
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, c/ Prof. García González 1, E-41012 Sevilla, Spain
| | - F Cardona
- Department of Chemistry 'Ugo Schiff', University of Firenze, via della Lastruccia 3-13, 50019 Sesto Fiorentino (FI), Italy; Associated with Consorzio Interuniversitario Nazionale di ricerca in Metodologie e Processi Innovativi di Sintesi (CINMPIS), Italy.
| |
Collapse
|
6
|
Bourebaba L, Bedjou F, Röcken M, Marycz K. Nortropane alkaloids as pharmacological chaperones in the rescue of equine adipose-derived mesenchymal stromal stem cells affected by metabolic syndrome through mitochondrial potentiation, endoplasmic reticulum stress mitigation and insulin resistance alleviation. Stem Cell Res Ther 2019; 10:178. [PMID: 31215461 PMCID: PMC6582509 DOI: 10.1186/s13287-019-1292-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2019] [Revised: 05/20/2019] [Accepted: 05/31/2019] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVES Equine metabolic syndrome (EMS) refers to a cluster of associated abnormalities and metabolic disorders, including insulin resistance and adiposity. The numerous biological properties of mesenchymal stem cells (MSCs), including self-renewal and multipotency, have been the subject of many in-depth studies, for the management of EMS; however, it has been shown that this cell type may be affected by the condition, impairing thus seriously their therapeutic potential. Therefore, an attempt to rescue EMS adipose-derived stem cells (ASCs) with calystegines (polyhydroxylated alkaloids) that are endowed with strong antioxidant and antidiabetic abilities was performed. METHODS ASCs isolated from EMS horses were subsequently treated with various concentrations of total calystegines. Different parameters were then assessed using flow cytometry, confocal as well as SE microscopy, and RT-qPCR. RESULTS Our results clearly demonstrated that calystegines could improve EqASC viability and proliferation and significantly reduce apoptosis, via improvement of mitochondrial potentiation and functionality, regulation of pro- and anti-apoptotic pathways, and suppression of ER stress. Furthermore, nortropanes positively upregulated GLUT4 and IRS transcripts, indicating a possible sensitizing or mimetic effect to insulin. Most interesting finding in this investigation lies in the modulatory effect of autophagy, a process that allows the maintenance of cellular homeostasis; calystegines acted as pharmacological chaperones to promote cell survival. CONCLUSION Obtained data open new perspectives in the development of new drugs, which may improve the metabolic dynamics of cells challenged by MS.
Collapse
Affiliation(s)
- Lynda Bourebaba
- Department of Experimental Biology, Faculty of Biology and Animal Science, Wrocław University of Environmental and Life Sciences, Norwida 27B, 50-375, Wrocław, Poland. .,International Institute of Translational Medicine, Jesionowa, 11, Malin, 55-114, Wisznia Mała, Poland.
| | - Fatiha Bedjou
- Laboratoire de Biotechnologies végétales et d'Ethnobotanique, Faculté des Sciences de la Nature et de la Vie, Université de Bejaia, 06000, Bejaia, Algeria
| | - Michael Röcken
- Faculty of Veterinary Medicine, Equine Clinic - Equine Surgery, Justus-Liebig-University, 35392, Gießen, Germany
| | - Krzysztof Marycz
- Department of Experimental Biology, Faculty of Biology and Animal Science, Wrocław University of Environmental and Life Sciences, Norwida 27B, 50-375, Wrocław, Poland. .,Faculty of Veterinary Medicine, Equine Clinic - Equine Surgery, Justus-Liebig-University, 35392, Gießen, Germany. .,International Institute of Translational Medicine, Jesionowa, 11, Malin, 55-114, Wisznia Mała, Poland.
| |
Collapse
|
7
|
Design of a New α-1- C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation. MOLECULES (BASEL, SWITZERLAND) 2018; 23:molecules23102683. [PMID: 30340368 PMCID: PMC6222826 DOI: 10.3390/molecules23102683] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 10/11/2018] [Accepted: 10/18/2018] [Indexed: 11/17/2022]
Abstract
Some point mutations in β-glucocerebrosidase cause either improper folding or instability of this protein, resulting in Gaucher disease. Pharmacological chaperones bind to the mutant enzyme and stabilize this enzyme; thus, pharmacological chaperone therapy was proposed as a potential treatment for Gaucher disease. The binding affinities of α-1-C-alkyl 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives, which act as pharmacological chaperones for β-glucocerebrosidase, abruptly increased upon elongation of their alkyl chain. In this study, the primary causes of such an increase in binding affinity were analyzed using protein–ligand docking and molecular dynamics simulations. We found that the activity cliff between α-1-C-heptyl-DAB and α-1-C-octyl-DAB was due to the shape and size of the hydrophobic binding site accommodating the alkyl chains, and that the interaction with this hydrophobic site controlled the binding affinity of the ligands well. Furthermore, based on the aromatic/hydrophobic properties of the binding site, a 7-(tetralin-2-yl)-heptyl-DAB compound was designed and synthesized. This compound had significantly enhanced activity. The design strategy in consideration of aromatic interactions in the hydrophobic pocket was useful for generating effective pharmacological chaperones for the treatment of Gaucher disease.
Collapse
|
8
|
García-Moreno MI, de la Mata M, Sánchez-Fernández EM, Benito JM, Díaz-Quintana A, Fustero S, Nanba E, Higaki K, Sánchez-Alcázar JA, García Fernández JM, Ortiz Mellet C. Fluorinated Chaperone-β-Cyclodextrin Formulations for β-Glucocerebrosidase Activity Enhancement in Neuronopathic Gaucher Disease. J Med Chem 2017; 60:1829-1842. [PMID: 28171725 DOI: 10.1021/acs.jmedchem.6b01550] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Amphiphilic glycomimetics encompassing a rigid, undistortable nortropane skeleton based on 1,6-anhydro-l-idonojirimycin and a polyfluorinated antenna, when formulated as the corresponding inclusion complexes with β-cyclodextrin (βCD), have been shown to behave as pharmacological chaperones (PCs) that efficiently rescue lysosomal β-glucocerebrosidase mutants associated with the neuronopathic variants of Gaucher disease (GD), including the highly refractory L444P/L444P and L444P/P415R single nucleotide polymorphs, in patient fibroblasts. The body of work here presented includes the design criteria for the PC prototype, the synthesis of a series of candidates, the characterization of the PC:βCD complexes, the determination of the selectivity profiles toward a panel of commercial and human lysosomal glycosidases, the evaluation of the chaperoning activity in type 1 (non-neuronopathic), type 2 (acute neuronopathic), and type 3 (adult neuronopathic) GD fibroblasts, the confirmation of the rescuing mechanism by immunolabeling, and the analysis of the PC:GCase binding mode by docking experiments.
Collapse
Affiliation(s)
- M Isabel García-Moreno
- Department of Organic Chemistry, Faculty of Chemistry, University of Sevilla , c/Profesor García González 1, 41011 Sevilla, Spain
| | - Mario de la Mata
- Centro Andaluz de Biología del Desarrollo (CABD), CSIC, Universidad Pablo de Olavide, and Centro de Investigación Biomédica en Red, Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Carretera de Utrera Km 1, 41013 Sevilla, Spain
| | - Elena M Sánchez-Fernández
- Department of Organic Chemistry, Faculty of Chemistry, University of Sevilla , c/Profesor García González 1, 41011 Sevilla, Spain
| | - Juan M Benito
- Instituto de Investigaciones Químicas (IIQ), CSIC, and Universidad de Sevilla, Avda. Américo Vespucio 49, E-41092 Sevilla, Spain
| | - Antonio Díaz-Quintana
- Instituto de Investigaciones Químicas (IIQ), CSIC, and Universidad de Sevilla, Avda. Américo Vespucio 49, E-41092 Sevilla, Spain
| | - Santos Fustero
- Departamento de Química Orgánica, Universidad de Valencia , 46100 Burjassot, Spain.,Laboratorio de Moléculas Orgánicas, Centro de Investigación Príncipe Felipe , 46012 Valencia, Spain
| | - Eiji Nanba
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University , 86 Nishi-cho, Yonago 683-8503, Japan
| | - Katsumi Higaki
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University , 86 Nishi-cho, Yonago 683-8503, Japan
| | - José A Sánchez-Alcázar
- Centro Andaluz de Biología del Desarrollo (CABD), CSIC, Universidad Pablo de Olavide, and Centro de Investigación Biomédica en Red, Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Carretera de Utrera Km 1, 41013 Sevilla, Spain
| | - José M García Fernández
- Instituto de Investigaciones Químicas (IIQ), CSIC, and Universidad de Sevilla, Avda. Américo Vespucio 49, E-41092 Sevilla, Spain
| | - Carmen Ortiz Mellet
- Department of Organic Chemistry, Faculty of Chemistry, University of Sevilla , c/Profesor García González 1, 41011 Sevilla, Spain
| |
Collapse
|
9
|
Sánchez-Fernández EM, García Fernández JM, Mellet CO. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem Commun (Camb) 2016; 52:5497-515. [PMID: 27043200 DOI: 10.1039/c6cc01564f] [Citation(s) in RCA: 112] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Lysosomal storage disorders (LSDs) are often caused by mutations that destabilize native folding and impair the trafficking of enzymes, leading to premature endoplasmic reticulum (ER)-associated degradation, deficiencies of specific hydrolytic functions and aberrant storage of metabolites in the lysosomes. Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are available for a few of these conditions, but most remain orphan. A main difficulty is that virtually all LSDs involve neurological decline and neither proteins nor the current SRT drugs can cross the blood-brain barrier. Twenty years ago a new therapeutic paradigm better suited for neuropathic LSDs was launched, namely pharmacological chaperone (PC) therapy. PCs are small molecules capable of binding to the mutant protein at the ER, inducing proper folding, restoring trafficking and increasing enzyme activity and substrate processing in the lysosome. In many LSDs the mutated protein is a glycosidase and the accumulated substrate is an oligo- or polysaccharide or a glycoconjugate, e.g. a glycosphingolipid. Although it might appear counterintuitive, substrate analogues (glycomimetics) behaving as competitive glycosidase inhibitors are good candidates to perform PC tasks. The advancements in the knowledge of the molecular basis of LSDs, including enzyme structures, binding modes, trafficking pathways and substrate processing mechanisms, have been put forward to optimize PC selectivity and efficacy. Moreover, the chemical versatility of glycomimetics and the variety of structures at hand allow simultaneous optimization of chaperone and pharmacokinetic properties. In this Feature Article we review the advancements made in this field in the last few years and the future outlook through the lessons taught by three archetypical LSDs: Gaucher disease, GM1-gangliosidosis and Fabry disease.
Collapse
Affiliation(s)
- Elena M Sánchez-Fernández
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Profesor García González 1, 41012, Sevilla, Spain.
| | - José M García Fernández
- Instituto de Investigaciones Químicas (IIQ), CSIC - Universidad de Sevilla, Avda. Américo Vespucio 49, 41092 Sevilla, Spain.
| | - Carmen Ortiz Mellet
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Profesor García González 1, 41012, Sevilla, Spain.
| |
Collapse
|
10
|
Wang HY, Kato A, Kinami K, Li YX, Fleet GWJ, Yu CY. Concise synthesis of calystegines B2 and B3via intramolecular Nozaki-Hiyama-Kishi reaction. Org Biomol Chem 2016; 14:4885-96. [PMID: 27161660 DOI: 10.1039/c6ob00697c] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The key step in the concise syntheses of calystegine B2 and its C-2 epimer calystegine B3 was the construction of cycloheptanone 8via an intramolecular Nozaki-Hiyama-Kishi (NHK) reaction of 9, an aldehyde containing a Z-vinyl iodide. Vinyl iodide 9 was obtained by the Stork olefination of aldehyde 10, derived from carbohydrate starting materials. Calystegines B2 (3) and B3 (4) were synthesized from d-xylose and l-arabinose derivatives respectively in 11 steps in excellent overall yields (27% and 19%).
Collapse
Affiliation(s)
- Hong-Yao Wang
- Beijing National Laboratory for Molecular Science (BNLMS), CAS Key Laboratory of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
| | | | | | | | | | | |
Collapse
|
11
|
Kato A, Nakagome I, Sato K, Yamamoto A, Adachi I, Nash RJ, Fleet GWJ, Natori Y, Watanabe Y, Imahori T, Yoshimura Y, Takahata H, Hirono S. Docking study and biological evaluation of pyrrolidine-based iminosugars as pharmacological chaperones for Gaucher disease. Org Biomol Chem 2016; 14:1039-48. [DOI: 10.1039/c5ob02223a] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
α-1-C-Alkylated 1,4-dideoxy-1,4-imino-d-arabinitols (DAB) derivatives as pharmacological chaperones for Gaucher disease.
Collapse
|
12
|
Kato A, Zhang ZL, Wang HY, Jia YM, Yu CY, Kinami K, Hirokami Y, Tsuji Y, Adachi I, Nash RJ, Fleet GWJ, Koseki J, Nakagome I, Hirono S. Design and Synthesis of Labystegines, Hybrid Iminosugars from LAB and Calystegine, as Inhibitors of Intestinal α-Glucosidases: Binding Conformation and Interaction for ntSI. J Org Chem 2015; 80:4501-15. [DOI: 10.1021/acs.joc.5b00342] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Atsushi Kato
- Department
of Hospital Pharmacy, University of Toyama, Toyama 930-0194, Japan
| | - Zhao-Lan Zhang
- Beijing
National Laboratory of Molecular Science (BNLMS), CAS Key Laboratory
of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
| | - Hong-Yao Wang
- Beijing
National Laboratory of Molecular Science (BNLMS), CAS Key Laboratory
of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
| | - Yue-Mei Jia
- Beijing
National Laboratory of Molecular Science (BNLMS), CAS Key Laboratory
of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
| | - Chu-Yi Yu
- Beijing
National Laboratory of Molecular Science (BNLMS), CAS Key Laboratory
of Molecular Recognition and Function, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China
| | - Kyoko Kinami
- Department
of Hospital Pharmacy, University of Toyama, Toyama 930-0194, Japan
| | - Yuki Hirokami
- Department
of Hospital Pharmacy, University of Toyama, Toyama 930-0194, Japan
| | - Yutaro Tsuji
- Department
of Hospital Pharmacy, University of Toyama, Toyama 930-0194, Japan
| | - Isao Adachi
- Department
of Hospital Pharmacy, University of Toyama, Toyama 930-0194, Japan
| | - Robert J. Nash
- Institute
of Biological, Environmental and Rural Sciences, Phytoquest Limited, Plas Gogerddan, Aberystwyth, Ceredigion SY23 3EB, United Kingdom
| | - George W. J. Fleet
- Chemistry Research Laboratory, 12 Mansfield Road, Oxford OX1 3TA, United Kingdom
- National
Engineering Research Center for Carbohydrate Synthesis, Jiangxi Normal University, Nanchang 330022, PR China
| | - Jun Koseki
- School of
Pharmaceutical Sciences, Kitasato University, Tokyo 108-8641, Japan
| | - Izumi Nakagome
- School of
Pharmaceutical Sciences, Kitasato University, Tokyo 108-8641, Japan
| | - Shuichi Hirono
- School of
Pharmaceutical Sciences, Kitasato University, Tokyo 108-8641, Japan
| |
Collapse
|